Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HydroVax-005 CHIKV Vaccine in Healthy Adults
NCT06669208Phase 1Completed
- Sponsor
- Najit Technologies, Inc.
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HydroVax-005 CHIKV in Chikungunya (CHIKV) (3 arms), sponsored by Najit Technologies, Inc. Primary endpoints: Serious Adverse Events, Adverse Events of Special Interest and 5 more. Started Nov 2024; status: completed.
02
Drugs
HydroVax-005 CHIKV
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT06669208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669208.